FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2025/05/086237 [Registered on: 05/05/2025] Trial Registered Prospectively
Last Modified On: 29/04/2025
Post Graduate Thesis  Yes 
Type of Trial  Interventional 
Type of Study   Drug
Preventive
Dentistry 
Study Design  Randomized, Parallel Group, Placebo Controlled Trial 
Public Title of Study   Use of QLC gel as an antibacterial agent in treatment of patients with gum disease. 
Scientific Title of Study   Formulation, physicochemical characterization and clinical evaluation of therapeutic potential of quercetin loaded chitosan nanoparticles in management of chronic periodontitis 
Trial Acronym  Nill 
Secondary IDs if Any  
Secondary ID  Identifier 
NIL  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  NIKESH NARAYAN A MOOLYA 
Designation  PHD STUDENT 
Affiliation  SMBT Dental College and Hospital Sangamner 
Address  Room no 1, PHD section, Division 2, Department of Periodontics, SMBT dental college and hospital, Sangamner

Ahmadnagar
MAHARASHTRA
4226068
India 
Phone  9987004390  
Fax  02425222867  
Email  moolyanikesh80@gmail.com  
 
Details of Contact Person
Scientific Query
 
Name  PURUSHOTTAM SAKHARAM RAKHEWAR 
Designation  Professor and Head of Department  
Affiliation  SMBT Dental College and Hospital Sangamner 
Address  Room no 1, PHD section, Division 2, Department of Periodontics, SMBT dental college and hospital, Sangamner

Ahmadnagar
MAHARASHTRA
42269068
India 
Phone  9370017343  
Fax  02425222867  
Email  drpsrakhewar@gmail.com  
 
Details of Contact Person
Public Query
 
Name  NIKESH NARAYAN A MOOLYA 
Designation  PHD STUDENT 
Affiliation  SMBT Dental College and Hospital Sangamner 
Address  Room no 1, PHD section, Division 2, Department of Periodontics, SMBT dental college and hospital, Sangamner

Ahmadnagar
MAHARASHTRA
4226068
India 
Phone  9987004390  
Fax  02425222867  
Email  moolyanikesh80@gmail.com  
 
Source of Monetary or Material Support  
SMBT dental college and hospital, Tq. Sangamner, Dist. Ahmednagar, Maharashtra, India. (Postal Code- 4226068). 
 
Primary Sponsor  
Name  Nikesh Narayana Moolya 
Address  SMBT dental college and hospital, Tq. Sangamner, Dist. Ahmednagar, Maharashtra, India. (Postal Code- 4226068). 
Type of Sponsor  Research institution and hospital 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr Ashok Patil  SMBT Dental College and Hospital, Sangamner 422608   Room no 1, PHD section, Division 2, Department of Periodontics
Ahmadnagar
MAHARASHTRA 
9011067110

dr.ashok@rediffmail.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
Commitee on Ethics, SMBT Dental College, Sangamner  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition: K053||Chronic periodontitis,  
 
Intervention / Comparator Agent  
Type  Name  Details 
Intervention  0.1% Quercetin Chitosan Nanoparticle Gel  Local drug delivery in Periodontal Pocket for 7 days 
Comparator Agent  Placebo Gel  Local drug delivery in Periodontal Pocket for 7 days 
 
Inclusion Criteria  
Age From  35.00 Year(s)
Age To  60.00 Year(s)
Gender  Both 
Details  Systemically healthy subjects with a minimum of 20 teeth.
Subjects with moderate chronic periodontitis and no other gingival lesions.
Subjects between the age group 35 to 60 years. No removable prosthesis or orthodontic bands or appliances worn at the time of study. 
 
ExclusionCriteria 
Details  Subjects with a history of any antibiotics, anti-inflammatory or antimicrobial mouth rinse usage or periodontal therapy in the preceding 3 months or during the study period.
Subjects with suspected allergy to any flavanoids, chitin based products, those on anticoagulant or steroid therapy, smokers, tobacco chewers, alcoholics, pregnant or lactating mothers.
Immunocompromised patients, dental infections like chronic periapical lesions, apthous stomatitis, oral lichen planus, non-compliant or physically challenged patients.
 
 
Method of Generating Random Sequence   Coin toss, Lottery, toss of dice, shuffling cards etc 
Method of Concealment   Not Applicable 
Blinding/Masking   Participant and Outcome Assessor Blinded 
Primary Outcome  
Outcome  TimePoints 
1. Plaque Index (PI) (Silness J, Loe H,1964)
2. Gingival Index (GI) (Loe H, Silness J,1963)
3. Modified Sulcus Bleeding Index (SBI) (Mombelli 1987)
4. Probing Pocket Depth (PPD) (measured from crest of the gingival margin to the base of the pocket) and
5. Relative Clinical Attachment Levels (CAL) (measured from the lower border of acrylic stent to the base of the pocket) to be recorded only for the selected sites by using a customized acrylic stent. (with UNC-15 probe) 
Baseline and Postoperatively 45 days 
 
Secondary Outcome  
Outcome  TimePoints 
Collection of Unstimulated Whole Saliva(UWS) samples
UWS to be collected at approximately the same time of day by the drooling method (Rhodus et al., 2005). Briefly, subjects asked to refrain from eating or drinking for 2 hours prior to saliva collection.
• At least 2ml of UWS to be collected by passively drooling into a chilled centrifuge tube for 5-10 minutes. The tubes to be codified and transferred on ice to the laboratory for processing. All samples to be centrifuged and the supernatant constituting clarified saliva to be separated and stored until further analysis.

Unstimulated whole saliva (UWS) sampling to be conducted to evaluate IL-1L1 beta levels and samples will be sent to Department of Biotechnology and Bioinformatics for processing and analysis
 
Baseline and Postoperatively 45 days 
 
Target Sample Size   Total Sample Size="45"
Sample Size from India="45" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   Phase 3 
Date of First Enrollment (India)   01/06/2025 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="0"
Months="10"
Days="0" 
Recruitment Status of Trial (Global)   Not Applicable 
Recruitment Status of Trial (India)  Not Yet Recruiting 
Publication Details   N/A 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - YES
  1. What data in particular will be shared?
    Response - Individual participant data that underlie the results reported in this article, after de-identification (text, tables, figures, and appendices).

  2. What additional supporting information will be shared?
    Response -  Study Protocol
    Response -  Statistical Analysis Plan
    Response - Clinical Study Report

  3. Who will be able to view these files?
    Response - Anyone

  4. For what types of analyses will this data be available?
    Response - Any purpose.

  5. By what mechanism will data be made available?
    Response - Proposals should be directed to [drmoolya@gmail.com].

  6. For how long will this data be available start date provided 10-02-2026 and end date provided 11-02-2033?
    Response - Immediately following publication. No end date.

  7. Any URL or additional information regarding plan/policy for sharing IPD? 
    Additional Information - nil
Brief Summary  
Introduction: Periodontitis is a chronic inflammatory disease initiated by plaque biofilm affecting the supporting structures of the teeth. It is a disease of multifactorial etiology, with involvement of microbial, genetic, environmental and host factors. The aim of periodontal treatment is primarily focused on eliminating the microorganisms and their by-products by means of mechanical instrumentation like scaling and root planing (SRP). It has been observed that the local route of drug delivery can attain 100-fold higher concentrations of an antimicrobial agent in subgingival sites compared with a systemic drug regimen thereby reducing the total patient dose by over 400 fold avoiding development of drug-resistant at non oral body sites. 
Quercetin is one of the bioflavonoid that is present in foods including vegetables, nuts, berries, legumes, green tea, onions and citrus. It has been approved by the United States Food and Drug Administration (FDA) as an ingredient in over-the-counter health supplement. To date, there has been no evidence in the literature of any adverse effects from consuming quercetin. Some of the antimicrobial effects of quercetin have been reported. 
Amongst various semi-synthetic polymers, chitosan, a deacetylated product of chitin is widely used in drug delivery devices Since it exhibits favorable biological properties such as non-toxicity biocompatibility, biodegradability and wound healing traits, it has attracted great attention in the pharmaceutical and biomedical fields. Chitosan based drug delivery system fulfill all these properties; it stays for extended periods in the oral cavity, has adequate drug penetration, shows excellent antimicrobial activity, high efficiency and acceptability.
Aim & objectives: To formulate, characterize physicochemical and evaluate clinical therapeutic potential of quercetin loaded chitosan nanoparticles in management of chronic periodontitis and to test Anti-inflammatory activity of the formulated gel in subjects with chronic periodontitis using ELISA. 
Methodology: 
• Preparation of chitosan and quercetin loaded chitosan nanoparticles-
Will be prepared according to the study by Zhang et al based on the ionic gelation of chitosan with Tripolyphosphate anions.
• Physico-chemical characterization studies- 
To determine the hydrodynamic diameter, morphology and particle size of nanoparticles using Transmission electron microscope.
To perform Spectroscopy characterization by UV-visible and Fourier transformed infrared technique (FTIR).
To determine antimicrobial activity of the synthesized QLC nanoparticle.
To determine water holding capacity of the QLC nanoparticles
To formulate gel with synthesized and characterized QLC nanoparticles using suitable polymer
•  Antioxidant potential of QLC nanoparticles- will be measured by 2,2-diphenyl-1-picrylhydazyl (DPPH) assay 
• Anti-microbial activity of QLC nanoparticles- shall be studied on the microorganisms referred to as initial colonizers of periodontal disease by conducting assays such as MIC and MBC according to study by Munot et al with minor modifications
• Formulation of therapeutic quercetin chitosan gel (QCG) using chitosan and QLC nanoparticles- 
An in-situ quercetin chitosan gel shall be prepared using suitable polymer post screening from the technique of gel forming injectable depot by Nair et al. The polymeric gelling agent shall be weighed to achieve a desired porosity and shall be placed for overnight mixing on magnetic stirrer. Post obtaining clear solution, the nanoparticles shall be added and will be mixed thoroughly. The gel will be allowed to set at room temperature and further gelation characteristics shall be studied.
• Anti-inflammatory activity assessment of QCG
In vivo study
The double blinded randomized controlled clinical study will be conducted from subjects selected from outpatient Department of Periodontology in the respective college. The selected 45 subjects to be divided into three equal groups (Group I, Group II and Group III). All the subjects meeting the inclusion criteria and willing to participate in the study with duly signed consent forms will be enrolled for the study. Group 1 and Group 2 subjects will be of chronic periodontitis and Group 3 subjects will be systemically healthy subjects without chronic gingivitis and periodontitis. 
Group I:  After baseline UWS sampling & clinical parameters ultrasonic scaling, polishing and root planing with appropriate gracey curettes in a single appointment to be carried out in fifteen subjects. No chemotherapeutic agents to be prescribed after treatment. This is followed by subgingival local drug delivery administration of of quercetin chitosan gel (QCG) into the selected site.
Group II: After baseline UWS sampling & clinical parameters ultrasonic scaling, polishing & root planing with appropriate gracey curettes in a single appointment to all to be carried out in fifteen subjects. This is followed by sub gingival local drug delivery administration of placebo gel into the selected site
Group III:  Fifteen Healthy subjects after a session of scaling and polishing will be subjected to UWS sampling
Both UWS sampling and assessment of clinical parameters to be recorded preoperatively at baseline (0 day) and post operatively at 45th day for Group I and Group II.

The analysis and interpretation of results of the clinical study by Enzyme linked immunoassay will be conducted at Department of Biotechnology and Bioinformatics in respective college.
Unstimulated salivary sampling assay to be evaluated by ELISA

Data collected will be compiled on to a MS Office excel worksheet and will be subjected to statistical analysis using an appropriate package like SPSS software. 

Expected outcome: Successful formulation of nanoparticles
 Antimicrobial and antioxidant properties of nanoparticles
Successful formulation of quercetin chitosan nanogel and antiplaque effect of quercetin chitosan gel. 
 
Close